$Lyell Immunopharma (LYEL.US)$ Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy Designation For LYL314 In Treatment Of Relapsed And/Or Refractory Large B-Cell Lymphoma

$Lyell Immunopharma (LYEL.US)$
Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma
Tuesday, 15th April at 9:00 am
• RMAT designation was granted based on promising clinical data from the ongoing Phase 1/2 trial of LYL314 in patients with relapsed and/or refractory large B-cell lymphoma.
• RMAT designation recognizes the potential of LYL314 to address significant unmet needs of ...

$Lyell Immunopharma (LYEL.US)$ New 13G’s recently showing J&J and Black Rock Got some shares!

$Lyell Immunopharma (LYEL.US)$ what a day

$Lyell Immunopharma (LYEL.US)$
Acquired ImmPACT Bio and strengthened clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate with strong Phase 1 clinical data in patients with aggressive relapsed/refractory B-cell non-Hodgkin’s lymphoma
Presenting initial data from Phase 1 multi-center clinical trial of IMPT-314 at the American Society of Hematology 2024...

$Lyell Immunopharma (LYEL.US)$
05/11/2024 - 22:30
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with solid tumors or hematologic malignancies, ...